Insmed Incorporated
INSM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.88 | -0.16 | -6.60 | -0.24 |
| FCF Yield | -6.23% | -12.63% | -16.69% | -12.13% |
| EV / EBITDA | -14.75 | -7.69 | -5.73 | -7.69 |
| Quality | ||||
| ROIC | -50.32% | -63.87% | -31.11% | -33.40% |
| Gross Margin | 76.43% | 78.52% | 77.53% | 76.57% |
| Cash Conversion Ratio | 0.75 | 0.72 | 0.83 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.02% | 17.43% | 14.28% | 11.36% |
| Free Cash Flow Growth | -28.44% | -33.93% | -10.72% | -63.86% |
| Safety | ||||
| Net Debt / EBITDA | -0.92 | -1.09 | -0.23 | 0.27 |
| Interest Coverage | -10.34 | -8.69 | -17.29 | -9.27 |
| Efficiency | ||||
| Inventory Turnover | 0.87 | 0.79 | 0.79 | 0.66 |
| Cash Conversion Cycle | 160.94 | 148.64 | 173.06 | 305.30 |